EPS: As of FY2025 Q2, the actual value is USD -0.11, beating the estimate of USD -0.12.<h3>Segment Revenue</h3><ul><li>HilleVax, Inc. has not generated any revenue since its inception and does not expect to generate revenue from product sales until successful development and regulatory approval of its norovirus vaccine candidates.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $5.3 million for the three months ended June 30, 2025, compared to a net loss of $40.7 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $11.3 million, compared to $87.5 million in 2024.</li><li>Operating Expenses: Total operating expenses were $6.985 million for the three months ended June 30, 2025, a decrease from $42.963 million in the same period in 2024. For the six months ended June 30, 2025, operating expenses were $14.589 million, down from $92.760 million in 2024.</li><li>Research and Development Expenses: These expenses were $1.328 million for the three months ended June 30, 2025, a significant decrease from $26.601 million in 2024. For the six months ended June 30, 2025, R&amp;D expenses were $3.311 million, down from $52.579 million in 2024.</li><li>General and Administrative Expenses: These expenses were $5.657 million for the three months ended June 30, 2025, compared to $8.127 million in 2024. For the six months ended June 30, 2025, these expenses were $11.278 million, down from $16.621 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $13.507 million for the six months ended June 30, 2025, compared to $62.781 million in 2024.</li><li>Investing Cash Flow: Net cash used in investing activities was $82.283 million for the six months ended June 30, 2025, compared to $61.130 million in 2024.</li><li>Financing Cash Flow: There were no financing activities during the six months ended June 30, 2025, compared to $15.677 million provided by financing activities in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: Stock-based compensation expense was $2.330 million for the three months ended June 30, 2025, compared to $6.061 million in 2024. For the six months ended June 30, 2025, it was $4.759 million, down from $11.255 million in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: HilleVax, Inc. is focused on developing and commercializing its norovirus vaccine candidates, with ongoing efforts to explore business development-related activities and strategic alternatives.</li><li>Non-Core Business: The company has entered into a merger agreement with XOMA, which is expected to close in September 2025. This strategic move is anticipated to provide additional resources and support for the company’s vaccine development efforts.</li></ul>

HilleVax | 10-Q: FY2025 Q2 EPS Beats Estimate at USD -0.11